Information regarding changes to the Board of Directors in QuickCool AB
At the EGM today, the shareholders of QuickCool AB voted to make changes to the board of QuickCool AB.
Four new board members have been elected: Patrick Marché, Balázs Tüske, Afnan M. Al Khalifa and Victor Humberdot. The vote was on the nomination of shareholder Biovation Sciences Limited. Göran Brorsson and Lennart Sjölund will remain as board members of QuickCool, with Göran Brorsson continuing in his role as Chairman of the board.
The four new board members bring new financing expertise and an international network to the Company to help with its fund raising efforts with a view to the long-term viability of QuickCool AB.
“Biovation is delighted to support QuickCool. With these changes to the board, combined with the continuity provided with Göran Brorsson and Lennart Sjölund staying on, the company will have the needed expertise to focus on the financing of the company and its financial viability,” said Edward Keller, representative of Biovation Sciences.
“We are delighted to have the support of Biovation Sciences, and the international investor expertise which the new board members bring,” noted Göran Brorsson. “This will support the company’s ability to finalize the development of the QuickCool platform, and enhance the future market possibilities of the Company.”
QuickCool would also like to thank the former board members of QuickCool who are stepping down as of today for their dedicated service to the company.
For additional information, please contact:
Fredrik Radencrantz, CEO
Phone: +46-46-286 38 40
E-mail: fredrik.radencrantz@quickcool.se
QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se
Tags: